Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 12,500 shares of Enliven Therapeutics stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total value of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares in the company, valued at $20,665,399.68. The trade was a 1.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock traded down $1.14 during trading on Tuesday, reaching $21.32. The company's stock had a trading volume of 258,864 shares, compared to its average volume of 269,232. Enliven Therapeutics, Inc. has a one year low of $15.96 and a one year high of $30.03. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -11.22 and a beta of 1.04. The business's fifty day moving average price is $21.32 and its 200-day moving average price is $23.79.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its holdings in Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Enliven Therapeutics during the 4th quarter worth about $97,000. BNP Paribas Financial Markets acquired a new stake in Enliven Therapeutics in the 4th quarter valued at about $112,000. ExodusPoint Capital Management LP acquired a new stake in Enliven Therapeutics in the 4th quarter valued at about $200,000. Finally, Brevan Howard Capital Management LP bought a new position in shares of Enliven Therapeutics in the fourth quarter worth about $228,000. Institutional investors own 95.08% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on ELVN. BTIG Research started coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a "buy" rating and a $42.00 price objective for the company. HC Wainwright increased their target price on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Enliven Therapeutics has a consensus rating of "Buy" and an average price target of $38.75.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.